CA2553436A1 - Peptides selectivement letaux pour des cellules mammiferes transformees et malignes - Google Patents
Peptides selectivement letaux pour des cellules mammiferes transformees et malignes Download PDFInfo
- Publication number
- CA2553436A1 CA2553436A1 CA002553436A CA2553436A CA2553436A1 CA 2553436 A1 CA2553436 A1 CA 2553436A1 CA 002553436 A CA002553436 A CA 002553436A CA 2553436 A CA2553436 A CA 2553436A CA 2553436 A1 CA2553436 A1 CA 2553436A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- seq
- derivative
- analog
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne des peptides correspondant à la totalité ou à une partie de résidus d'acide aminé 12-26 de la protéine p53. Ces peptides sont létaux pour des cellules transformées et malignes, lorsqu'ils sont fusionnés à une séquence de tête de pénétration membranaire. Pour réduire la protéolyse d'un tel peptide, au moins un acide aminé D peut être substitué par des acides aminés L correspondants de la partie p53 et/ou de la tête de pénétration membranaire du peptide. En outre, une liaison pseudopepditique ou une liaison pseudopeptidique rétro/inverso peut être substituée par au moins une liaison peptidique dans la séquence p53 ou dans la séquence de tête de pénétration membranaire, ou dans les deux, de sorte à rendre le peptide susmentionné moins prédisposé à une protéolyse. En outre, à la fois la séquence de tête de pénétration membranaire et la partie p53 du peptide susmentionné peuvent comprendre des isomères rétro/inverso et des isomères rétro/inverso partiellement modifiés. De tels isomères sont moins sensibles à une protéolyse, et présentent par conséquent des demi-vies prolongées. Les peptides susmentionnés sont utiles pour traiter une maladie néoplastique chez un animal, de préférence un humain. L'invention concerne des compositions pharmaceutiques comprenant les peptides susmentionnés mélangés à un excipient pharmaceutiquement acceptable. L'invention concerne des méthodes de traitement d'une maladie néoplastique chez un patient. Ces méthodes consistent à administrer un peptide susmentionné fusionné à son extrémité carboxyterminale à une séquence de tête de pénétration membranaire. L'invention concerne également des méthodes pour évaluer le niveau d'efficacité d'un peptide susmentionné pour tuer in vitro des cellules néoplastiques ou des cellules transformées ou des cellules malignes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2004/000684 | 2004-01-13 | ||
| PCT/US2004/000684 WO2004081030A2 (fr) | 2003-03-12 | 2004-01-13 | Peptides selectivement letaux pour les cellules malignes et transformees |
| PCT/US2004/044073 WO2006006954A2 (fr) | 2004-01-13 | 2004-12-22 | Peptides selectivement letaux pour des cellules mammiferes transformees et malignes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2553436A1 true CA2553436A1 (fr) | 2006-01-19 |
Family
ID=35784274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002553436A Abandoned CA2553436A1 (fr) | 2004-01-13 | 2004-12-22 | Peptides selectivement letaux pour des cellules mammiferes transformees et malignes |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1706419A2 (fr) |
| JP (1) | JP2008505846A (fr) |
| AU (1) | AU2004321478A1 (fr) |
| CA (1) | CA2553436A1 (fr) |
| WO (1) | WO2006006954A2 (fr) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1490089A4 (fr) * | 2002-03-12 | 2006-08-30 | Univ New York State Res Found | Peptides selectivement letaux pour des cellules de mammiferes transformees et malignes |
-
2004
- 2004-12-22 JP JP2006549329A patent/JP2008505846A/ja active Pending
- 2004-12-22 EP EP04822147A patent/EP1706419A2/fr not_active Withdrawn
- 2004-12-22 WO PCT/US2004/044073 patent/WO2006006954A2/fr not_active Application Discontinuation
- 2004-12-22 CA CA002553436A patent/CA2553436A1/fr not_active Abandoned
- 2004-12-22 AU AU2004321478A patent/AU2004321478A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004321478A1 (en) | 2006-01-19 |
| WO2006006954A3 (fr) | 2006-07-13 |
| EP1706419A2 (fr) | 2006-10-04 |
| WO2006006954A2 (fr) | 2006-01-19 |
| JP2008505846A (ja) | 2008-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1811033B1 (fr) | Inhibiteurs peptidiques à perméabilité cellulaire du processus de transduction du signal de JNK | |
| US8278413B2 (en) | Cell-permeable peptide inhibitors of the JNK signal transduction pathway | |
| EP1735335B1 (fr) | Peptide d'elimination cellulaire | |
| US6677116B1 (en) | Methods for treating cancer by modulating β-catenin mediated gene expression | |
| US8063012B2 (en) | Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor | |
| KR20040026686A (ko) | 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드 | |
| US7745405B2 (en) | Peptides selectively lethal to malignant and transformed mammalian cells | |
| US20050245451A1 (en) | Peptides selectively lethal to malignant and transformed mammalian cells | |
| CA2477878C (fr) | Peptides selectivement letaux pour des cellules de mammiferes transformees et malignes | |
| CA2553436A1 (fr) | Peptides selectivement letaux pour des cellules mammiferes transformees et malignes | |
| CA3121300A1 (fr) | Agents de liaison a dpep-1 et leurs methodes d'utilisation | |
| US20040254099A1 (en) | Compounds and methods for modulating beta-catenin mediated gene expression | |
| KR20160140147A (ko) | 심장 허혈후 재관류 손상에 의한 심장 질환 치료 및 예방용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20081222 |